GLP1R and Other metabolic disease: However, with the impressive results of GLP1-RAs and SGLT-2is on both the metabolic front and the associated CV outcomes, these molecules have come into focus in the management of a broad range of metabolic disorders, such as non-alcoholic fatty liver disease, sleep apnoea, and PCOS (26–28).